HoldsUp

Elizabeth Parrish

Elizabeth Parrish is a researcher in the field of gene therapy. Her published work investigates gene therapy approaches for healthy life extension, including intranasal and injectable methods, as well as the assessment of biosimilar gene therapies.

22 claims checked on air: 2 context 1 contradicted 4 overstated 8 supported 7 unverified

What they said on air - overstated

0:10:18overstatedlowIs Aging a Disease? Inside the First Human Gene Therapy Expe

Diseases of aging are typically diagnosed and cells enter senescence when telomeres shorten to about 5,000 base pairs.

"the diseases of aging that you are diagnosed with come when they're at about 5,000 base pairs. Your cells then go senescent so they no longer divide." (said at 0:10:18)

While in vitro studies of human somatic cells show that replicative senescence (permanent cessation of cell division) occurs after progressive telomere loss when mean terminal restriction fragment lengths reach critical thresholds (often cited in the range of 4 to 6 kilobases, or ~5,000 base pairs), clinical diseases of aging are multifactorial. Although short leukocyte telomere length correlates with increased risk for various age-related diseases, there is no universal threshold of 5,000 base pairs at which clinical diseases are diagnosed, and individual chromosome ends can trigger DNA damage responses and senescence before mean telomere length reaches a fixed numerical cutoff.

0:22:50overstatedlowIs Aging a Disease? Inside the First Human Gene Therapy Expe

In COVID-19, immune senescence characterized by short telomeres in T lymphocytes was a lethal factor.

"As we saw in COVID, immune senescence, meaning short telomeres in your immune system, was a lethal cause of death in that condition. And so when they tested people's telomeres in their T lymphocytes after death, they all had exhausted immune systems." (said at 0:22:50)

Observational studies and theoretical models show that shorter telomere length in peripheral blood lymphocytes or leukocytes is associated with increased severity and mortality risk in COVID-19 patients, and autopsy lung tissue from COVID-19 non-survivors showed signs of cellular senescence. However, the speaker overstates this by claiming that short telomeres in T lymphocytes were a definitive "lethal cause of death" and that post-mortem testing showed "they all had exhausted immune systems." In published studies, shorter telomeres are a risk factor and correlation rather than an established singular cause of death, and post-mortem analyses have examined small autopsy cohorts demonstrating senescence markers in lung tissue rather than a universal finding of complete immune exhaustion across all deceased patients.

0:34:50overstatedvery lowIs Aging a Disease? Inside the First Human Gene Therapy Expe

Lengthening telomeres reduces neurofibrillary tau tangles in neurons.

"Also lengthening the telomeres created less tau tangles in neurons and so we're excited about that." (said at 0:34:50)

Preclinical models demonstrate that telomere attrition and telomere-driven cellular senescence accelerate tau hyperphosphorylation, truncation, and neurofibrillary aggregation in tauopathy mouse models. However, stating definitively that lengthening telomeres reduces tau tangles in neurons overstates the current evidence, which is confined to preliminary animal and cellular studies rather than established human clinical trials.

0:45:22overstatedlowIs Aging a Disease? Inside the First Human Gene Therapy Expe

Follistatin enhances brain plasticity, reduces TGF-beta inflammatory markers, and is protective against breast and prostate cancers.

"follistatin it's turned out since uh I did that in 2015 is actually involved in a myriad of different biological processes including brain plasticity and that was not known reducing TGF-beta inflammatory markers that was not known. Um it's believed to be protective against both breast and prostate cancer." (said at 0:45:22)

Follistatin (FST) is well-characterized as an antagonist of TGF-beta/activin superfamily signaling pathways. Observational and cell-line research indicates that low follistatin expression correlates with poorer clinical outcomes in specific breast cancer subtypes (such as triple-negative breast cancer), and knockdown of FST increases tumor cell proliferation and invasion in vitro. However, describing follistatin as globally protective against breast and prostate cancers overstates the existing evidence, as its roles are complex, context-dependent, and primarily supported by preclinical models and retrospective tissue databases rather than established clinical preventive effects.

Fact-checked episodes

Publications